Johnson & Johnson, a pharmaceutical, and medical technologies corporation, completed the acquisition of Laminar, a medical device company focused on eliminating the left atrial appendage in patients with non-valvular atrial fibrillation, for $400m. “For the millions of people living with AFib, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners. We are looking forward to advancing this vision as part of Johnson & Johnson MedTech," Randy Lashinski, Laminar President & CEO.